"Veel mensen zijn door een ziekte afhankelijk van medicijnen. Goede medicijnen maken hun leven beter. Hiervoor is veel onderzoek nodig. Dat doen we bij ICON, samen met gezonde deelnemers. Wereldwijd is ICON de grootste onafhankelijke onderzoeker van geneesmiddelen. In Nederland werken ruim 1.000 mensen, zoals artsen, onderzoekers en verpleegkundigen, die elk nieuw middel uitgebreid testen. Aan de onderzoeken doen een heleboel gezonde deelnemers mee, en soms ook patiënten. Pas na veelvuldig onderzoek met goede resultaten mag een nieuw middel worden voorgeschreven. Deelnemers aan geneesmiddelenonderzoek zijn dus ontzettend belangrijk om patiënten zo snel mogelijk te kunnen helpen met een nieuw of beter medicijn."

During the past decade, PRA-EDS conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "PRA-EDS" #1 sponsor was "G1 Therapeutics, Inc." with 2 trials, followed by "Amolyt Pharma" with 1 trials sponsored, "Enyo Pharma" with 1 trials sponsored, "Galapagos NV" with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "PRA-EDS" #1 collaborator was "PRA Health Sciences" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "PRA-EDS" are "Healthy Volunteers" (2 trials), "Chronic Hypoparathyroidism" (1 trials), "Fungal Infection" (1 trials), "Healthy" (1 trials) and "Hepatitis B, Chronic" (1 trials). Many other conditions were trialed in "PRA-EDS" in a lesser frequency.

Most popular intervention types in "PRA-EDS" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "APX001" (1 trials), "AZP-3601" (1 trials), "EYP001a" (1 trials) and "G1T28-1 (CDK 4/6 Inhibitor)" (1 trials). Other intervention names were less common.

The vast majority of trials in "PRA-EDS" are 5 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "PRA-EDS". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in PRA-EDS, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in PRA-EDS, 6 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".